Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Genome
- DNA
- Proteins
- Test/Monitoring
- Delivery
- Disease
- Therapeutic
- Personal Care
- Antibody
- Cancer
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203497
The Licensor Break-through Invention shall be an invention that is the result of extraordinary research and development activities and shall result from or be based on materially new and/or different application(s) of Shuffling, as compared to technology already in-licensed by Licensee hereunder or from third party or otherwise available to Licensee, that was neither invented nor foreseen by Licensor as of the Effective Date, thereby enabling Licensee to develop either new market(s) or materially improved profitability in existing markets for Industrial Proteins, including but not limited to materially reducing the cost of a manufacturing process, as compared to average existing industrial enzymes markets.
The term Shuffling shall mean new methods for recombination of genetic material for creation and screening of genetic diversity. The term In Vitro Shuffling shall mean Shuffling where the gene recombination event occurs outside of a cell, but shall not include any Assay Technology. The term In Vivo Shuffling shall mean Shuffling where the gene recombination event occurs inside of a cell, but shall not include any Assay Technology.
• textiles and leather,
• laundry and cleaning products,
• starch processing, which shall include carbohydrate synthesis and modification as they may be applicable to starch processing,
• baking,
• food (including, without limitation, fats and oil, protein hydrolysates, bulk flavor ingredients, thickeners, emulsifiers, texturizers, alcohol, brewing products, vegetable and fruit processing, wine, juice, OTC digestive aids that have never been non-OTC pharmaceutical products,
• feed,
• personal care products, skin care (including bath and shower) and hygiene products, but not including any therapeutic or pharmaceutical products,
• paper and pulp manufacture,
• oil drilling,
• dyestuffs and dyeing processes, insofar as no pathways other than Industrial Protein Expression Pathways are Shuffled,
• wood, pulp, paper, lignin, and cellulose processing,
• The Licensee Preferred Area(s) upon activation by Licensee as well as the use of Shuffling for the development of organisms and vectors for the expression of the foregoing Industrial Proteins, including, but not limited to, the use of Shuffling to improve Industrial Protein Expression Pathways and competency of recombinant hosts, provided that the use of such organisms and vectors by Licensee or its Affiliates or licensees shall be limited to such purpose.
IPSCIO Record ID: 142882
RACHITT (an acronym for Random Chirmaragenesis on Transient Templates) is a proprietary gene shuffling method.
Gene shuffling is a powerful method to create millions of new variant genes coding for enzymes with altered properties. Gene shuffling technologies are molecular biology techniques used to combine desirable properties of a number of different genes into a single hybrid gene. Such technologies are typically used as part of a directed evolution strategy to improve the properties of particular enzymes or other proteins.
IPSCIO Record ID: 203330
For the research license, Licensor grants a non-exclusive, non-sublicensable, but exercisable by a Third Party, license, under the Licensed IP, for internal research purposes other than the discovery of Compounds.
Licensor grants a first right to negotiate pursuant to which Licensor shall notify Licensee in writing if it wishes to license to another party rights to develop and/or commercialize a given Ex Vivo Application; and provide to Licensee all material information related to such Ex Vivo Application that exists and is available to Licensor at the time of such notification.
Licensor grants a first right to negotiate pursuant to which Licensor shall notify Licensee in writing if it wishes to license to another party rights to develop and/or commercialize a given Licensor Compound; identify in such notice the Therapeutic Area in which Licensor is developing, or intends to develop, such Licensor Compound; and provide to Licensee all material information related to such Licensor Compound that exists and is available to Licensor at the time of such notification.
The Licensed Product means any Valid Claim Product, Licensee Modified Product, Know-How Product and/or Non-Collaboration Product, mean a Licensed Product that contains a unique Lead Compound, which includes the salts, solvates, isomers, polymorphs and prodrugs of such Lead Compound. Notwithstanding the foregoing, if Licensor performs Funded Work on any salts, solvates, isomers, polymorphs and/or prodrugs of a given Lead Compound, each new Lead Compound resulting from such Funded Work shall be deemed a unique Lead Compound.
A Valid Claim Product means any formulation of a Lead Compound that is Covered by the Licensed IP; provided, however, Valid Claim Product excludes any Licensee Modified Product; Licensed Product that is Covered by a Licensee Collaboration Patent and is not Covered by either a Licensor Collaboration Patent or a Joint Collaboration Patent; and Non-Collaboration Product.
A Know-How Product means any formulation of a Lead Compound that is not a Valid Claim Product, a Licensee Modified Product, or a Non-Collaboration Product.
If Licensor does not perform Funded Work on such Lead Compound, any formulation of such Lead Compound shall be referred to as a Non-Collaboration Product.
The Compound means any molecule that, as one of its primary mechanisms of therapeutic action, specifically binds to or interacts with at least one component of the Wnt Pathway and/or modulates the signaling of the Wnt Pathway; provided, however, Compound shall exclude any molecule that is or incorporates
– a polypeptide (e.g., an antibody, antibody fragment, peptide, protein) or a nucleic acid (e.g., antisense, RNAi oligos, DNA);
– an antagonist of the Hedgehog Pathway that was tested under the Hedgehog Agreement for activity in modulating the signaling of the Hedgehog Pathway before being tested under this Agreement, in which case, such molecule shall be governed by the Hedgehog Agreement; or
– a molecule that is independently developed by Licensee or in-licensed by Licensee, including as may be subsequently modified by Licensee, from a Third Party, in the case of either, unless Licensee elects, in its sole discretion, by written notice to Licensor at any time while the Licensee License is in effect, to include such molecule as a Compound.
The Wnt Pathway means a signaling pathway activated by any Wnt protein. where the components of such pathway include. but are not limited to, frizzled receptors, B-catenin, Bcl9/legless, CBP, TCF/LEF and Pygopus.
This new collaboration, in which Licensor will work exclusively with Licensee, involves the discovery and development of small molecule modulators of an undisclosed pathway that plays an important role in cell proliferation. This pathway is a key regulator of tissue formation and repair, and its abnormal activation is associated with certain cancers.
IPSCIO Record ID: 203290
For Exclusive Biomolecule License, Licensor grants to the Swiss Licensee and its Affiliates an exclusive, worldwide license, with the right to sublicense, under the Patent Rights and Know-How Controlled by Licensor and its Affiliates
– (A) to make, have made, and use all of the Existing Biomolecules that demonstrated the minimum criteria levels specified in the applicable Project Plans under the Research Collaboration Agreement prior to the Effective Date and that are produced using any means of production to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Former Licensee Exclusive Field, the Licensee Exclusive Field, the Biofuel Field, and/or Other Existing Research;
– (B) to make, have made, and use all of the Existing Biomolecules that have not demonstrated the minimum criteria levels specified in the applicable Project Plans under the Research Collaboration Agreement prior to the Effective Date and that are produced using Transgenic Expression to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Licensee Exclusive Field;
– (C) to make, have made, and use those specific Existing Biomolecules listed that have not demonstrated the minimum criteria levels specified in the applicable Project Plans under the Research Collaboration Agreement prior to the Effective Date and that are produced using any means of production including Fermentation and Transgenic Expression to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Animal Feed Field;
– (D) to make, have made, and use those specific Existing Biomolecules listed that have not demonstrated the minimum criteria levels specified in the applicable Project Plans under the Research Collaboration Agreement prior to the Effective Date and that are produced using any means of production including Fermentation and Transgenic Expression to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Biofuel Field and/or the Animal Feed Field;
– (E) to make, have made, and use all of the Biomolecules discovered or identified under the Research Program that are produced using Transgenic Expression to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Licensee Exclusive Field and/or the Other Existing Research;
– (F) to make, have made, and use all of the Subsequent Biomolecules referenced that are produced using Transgenic Expression to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Licensee Exclusive Field; and
– (H) to use for any purpose fermentable sugars, other chemicals and/or byproducts resulting from conversion of Biomass (such as lignins) in each case that result from exercise of the rights under any of the foregoing licenses.
For Non-Exclusive Biomolecule License, Licensor grants to the Swiss Licensee and its Affiliates a non-exclusive license, with the right to sublicense, under the Patent Rights and Know-How Controlled by Licensor and its Affiliates
– (A) to make, have made and use any Biomolecules discovered or identified under the Research Program that demonstrate the minimum criteria levels specified in the applicable Project Plans on or after the Effective Date and that are produced by Fermentation and included as a component in a Mixed Delivery Product to use, develop, make, have made, import, sell, offer for sale and have sold such Mixed Delivery Product for use in the Animal Feed Field and/or Biofuel Field;
– (B) to make, have made and use all of the Subsequent Biomolecules referenced that are produced by Fermentation and included as a component in a Mixed Delivery Product to use, develop, make, have made, import, sell, offer for sale and have sold Licensee Products for use in the Animal Feed Field and/or Biofuel Field; and
– (C) to use for any purpose fermentable sugars, other intermediate chemicals and/or byproducts resulting from conversion of Biomass (such as lignins) in each case that result from exercise of the rights under any of the foregoing licenses.
For the License of TMRI Platform Technology Improvements, Licensor grants the Swiss Licensee and its Affiliates an irrevocable, worldwide license, with the right to sublicense, to use the TMRI Platform Technology Improvements which are owned or otherwise Controlled by Licensor, in the Licensee Exclusive Field and in the Former Licensee Exclusive Field, it being understood and agreed that such license shall be exclusive during the Research Term and thereafter, such license shall be non-exclusive.
“Biomolecule†means any Gene, RNA, and protein or chemical entity the synthesis of which is directed by such Gene or Gene pathway, which protein or chemical entity was produced by an organism.
“Fermentation†means a microbial fermentation process, including, without limitation, bacterial-, fungal- and yeast-based fermentation.
Biofuel Field†means the hydrolytic conversion of Biomass to fermentable sugars and/or other chemicals for use in fuel production. For the avoidance of doubt, the “Biofuel Field†shall not include the pre-treatment of Biomass to make it suitable for hydrolysis or the development and use of organisms designed to ferment the products of hydrolysis to fuels and/or other chemicals.
“Biomass†means material that originates from Plants which can be or is intended to be used as a feedstock in the research, development and/or production of biofuels and bioproducts, including without limitation bioethanol, biodiesel, other fuels for energy applications and chemicals for any purpose, including without limitation agricultural, food and non-food crops and their residues and wastes (e.g. normally non-food material from crops such as stalks, leaves, husks, seed fiber, hulls), forestry residues and wastes (e.g. wood chips, sawdust, cardboard, pressboard, dead trees, tree branches), municipal solid waste (e.g. household garbage and paper products), food processing and other industrial wastes, energy crops (e.g. fast growing trees and grasses grown for this purpose), including, but not limited to, corn stover, switchgrass, and sugar cane bagasse, as well as trees; Biomass is often significantly composed of cellulose, hemi cellulose and lignin structures and may also include oil crops and starch components of crops.
IPSCIO Record ID: 128301
Licensor grants a non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee research genes exercisable during the research term of this Agreement.
Licensor grants an exclusive worldwide license, with the right to grant sublicenses, under Licensor Technology and Patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.
IPSCIO Record ID: 203979
Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.
With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license. Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.
